Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.

Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.

PURPOSE: Enhanced tumor cell survival through expression of inhibitors of apoptosis (IAP) is a hallmark of cancer. Survivin, an IAP absent from most normal tissues, is overexpressed in many malignancies and associated with a poorer prognosis. We report the first-in-human dose study of LY2181308, a s...

Full description

Bibliographic Details
Main Authors: Talbot, D, Ranson, M, Davies, J, Lahn, M, Callies, S, André, V, Kadam, S, Burgess, M, Slapak, C, Olsen, A, McHugh, P, de Bono, J, Matthews, J, Saleem, A, Price, P
Format: Journal article
Language:English
Published: 2010

Similar Items

Similar Items